562 related articles for article (PubMed ID: 17847044)
1. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists.
Fintel DJ
Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044
[TBL] [Abstract][Full Text] [Related]
2. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
3. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
4. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Gebel JM
J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
[TBL] [Abstract][Full Text] [Related]
5. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
8. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Diener HC
Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
[TBL] [Abstract][Full Text] [Related]
9. Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.
Ruland S
Drug Saf; 2008; 31(6):449-58. PubMed ID: 18484780
[TBL] [Abstract][Full Text] [Related]
10. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
11. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
13. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Hills NK; Johnston SC
Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
[TBL] [Abstract][Full Text] [Related]
14. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
15. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Simmons BB; Yeo A; Fung K; ;
Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
17. MATCH results: implications for the internist.
Lutsep HL
Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
[TBL] [Abstract][Full Text] [Related]
18. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Hacke W
Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
[TBL] [Abstract][Full Text] [Related]
19. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
20. Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Davis KA; Miyares MA; Dietrich E
Am J Health Syst Pharm; 2015 Oct; 72(19):1623-9. PubMed ID: 26386103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]